Literature DB >> 22391123

Epigenetic biomarkers in prostate cancer: Current and future uses.

Karen Chiam1, Carmela Ricciardelli, Tina Bianco-Miotto.   

Abstract

Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; DNA methylation; Epigenetics; Histone modifications; MicroRNAs; Prostate cancer

Mesh：

Substances：

Year:  2012        PMID： 22391123     DOI： 10.1016/j.canlet.2012.02.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  32 in total

1.  Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.

Authors:  Shanshan Zhao; Milan S Geybels; Amy Leonardson; Rohina Rubicz; Suzanne Kolb; Qingxiang Yan; Brandy Klotzle; Marina Bibikova; Antonio Hurtado-Coll; Dean Troyer; Raymond Lance; Daniel W Lin; Jonathan L Wright; Elaine A Ostrander; Jian-Bing Fan; Ziding Feng; Janet L Stanford
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

Review 2.  Clinically relevant genetic characterization of prostate tumors: how close are we to the goal?

Authors:  Yuri Tolkach; Florian Imkamp; Konstantin Godin; Hendrik Van Poppel
Journal:  Korean J Urol       Date:  2015-01-30

3.  Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.

Authors:  Yu Wu; Jerry Davison; Xiaoyu Qu; Colm Morrissey; Barry Storer; Lisha Brown; Robert Vessella; Peter Nelson; Min Fang
Journal:  Epigenetics       Date:  2016-02-18       Impact factor: 4.528

Review 4.  DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.

Authors:  Javier C Angulo; Jose I López; Santiago Ropero
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

5.  Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

Authors:  David Olmos; Daniel Brewer; Jeremy Clark; Daniel C Danila; Chris Parker; Gerhardt Attard; Martin Fleisher; Alison Hm Reid; Elena Castro; Shahneen K Sandhu; Lorraine Barwell; Nikhil Babu Oommen; Suzanne Carreira; Charles G Drake; Robert Jones; Colin S Cooper; Howard I Scher; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-10-09       Impact factor: 41.316

6.  The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer.

Authors:  Prashant Kumar Singh; Moray J Campbell
Journal:  Cancers (Basel)       Date:  2013-08-09       Impact factor: 6.639

7.  Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis.

Authors:  Alexey A Dmitriev; Eugenia E Rosenberg; George S Krasnov; Ganna V Gerashchenko; Vasily V Gordiyuk; Tatiana V Pavlova; Anna V Kudryavtseva; Artemy D Beniaminov; Anastasia A Belova; Yuriy N Bondarenko; Rostislav O Danilets; Alexander I Glukhov; Aleksandr G Kondratov; Andrey Alexeyenko; Boris Y Alekseev; George Klein; Vera N Senchenko; Vladimir I Kashuba
Journal:  Dis Markers       Date:  2015-09-28       Impact factor: 3.434

8.  Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer.

Authors:  Liang Kee Goh; Natalia Liem; Aadhitthya Vijayaraghavan; Gengbo Chen; Pei Li Lim; Kae-Jack Tay; Michelle Chang; John Soon Wah Low; Adita Joshi; Hong Hong Huang; Emarene Kalaw; Puay Hoon Tan; Wen-Son Hsieh; Wei Peng Yong; Joshi Alumkal; Hong Gee Sim
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

Review 9.  Novel tools for prostate cancer prognosis, diagnosis, and follow-up.

Authors:  Andreas Dimakakos; Athanasios Armakolas; Michael Koutsilieris
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

10.  Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.

Authors:  Ying-Li Lin; Pei-Gen Xie; Li Wang; Jian-Guo Ma
Journal:  Med Sci Monit       Date:  2014-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.